1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow FLT3 Internal Tandem Duplication: new trials by email Literature Review of FLT3 Internal Tandem Duplication trials Research Report on FLT3 Internal Tandem Duplication
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Laboratory Biomarker Analysis, Nintedanib - Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement | Phase 1 | Active not recruiting | Northwestern University | 44 | 2018-11-14 | 2025-10-21 |
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Azacitidine (1) · nintedanib (1)
United States (1)
Jessica Altman (1)
P30CA060553 (1)